Victoria Maroulis

Victoria Maroulis is a prominent patent litigation attorney and a Partner at Quinn Emanuel Urquhart & Sullivan, LLP, where she serves as the Managing Partner of the Silicon Valley Office and Co-Chair of the firm's National Intellectual Property Litigation Practice and Life Science Practice. Her practice encompasses a broad range of intellectual property matters, including patents, copyrights, trademarks, and trade secrets. She frequently handles cases across diverse technology sectors such as telecommunications, software, hardware, semiconductors, medical devices, and biotechnology.

Maroulis consistently represents defendants, particularly operating companies, in high-stakes patent disputes. Her record includes four tracked defendant-side appearances and no plaintiff-side appearances, reflecting a strong preference for defending innovator companies. She has acted as lead counsel in significant cases, including Motive Technologies, Inc. v. Samsara, Inc., and has represented major clients like Samsung, Genentech, Cisco, Varian Medical Systems, Natera, and Juul Labs.

Her notable achievements include serving as trial counsel for Samsung in its extensive patent, design patent, and trade dress disputes with Apple across district courts, the Federal Circuit, the U.S. Supreme Court, and the International Trade Commission (ITC). Maroulis also obtained a summary judgment of non-infringement for Genentech, which was affirmed by the Federal Circuit, and secured a complete summary judgment of non-infringement and invalidity for Cisco, Belkin, NETGEAR, and D-Link in a wireless router patent case, also affirmed by the Federal Circuit. More recently, she secured a preliminary injunction for Natera and won an ITC case for Juul Labs. She also secured an anti-suit injunction for Samsung against Huawei in Chinese patent proceedings.

Maroulis has significant experience in post-grant proceedings, including Inter Partes Reviews (IPRs). She achieved a complete victory for Celgene Corporation in an IPR challenging a patent related to its Revlimid® drug product. She earned her J.D. from Yale Law School in 1995 and a B.A. from Stanford University in 1992. She is admitted to practice in California and New York.